Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer

Current Medicinal Chemistry

Volumn 19, Issue 22, 2012, Pages 3689-3700

  Passaro, A ^a   Palazzo, A ^a   Trenta, P ^a   Mancini, M L ^a   Morano, F ^a   Cortesi, E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ALK; BRCA1; c MET; EGFR; ERCC1; KRAS; NSCLC; Predictive biomarkers

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLOXURIDINE PHOSPHATE; GEFITINIB; GELATINASE B; GEMCITABINE; K RAS PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NUCLEIC ACID BINDING PROTEIN; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN P53; SCATTER FACTOR MONOCLONAL ANTIBODY; SCATTER FACTOR RECEPTOR; THYMIDYLATE SYNTHASE; TIVANTINIB; TUMOR MARKER; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DIARRHEA; DNA REPAIR; DNA SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; FATIGUE; FUSION GENE; GENE DOSAGE; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

BIOLOGICAL MARKERS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYMIDYLATE SYNTHASE;

EID: 84865288107     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801661149     Document Type: Review

References (100)

1. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer.; Sandler, A.; Krook.; Zhu, J.; Johnson, D.H.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 2002, 346:92-98 (Pubitemid 34438899)
2. Bearz, A.; Berretta, M.; Lleshi, A.; Tirelli, U. Target therapies in lung cancer. J. Biomed. Biotechnol., 2011, 2011:921231
3. Sudhindra, A.; Ochoa, R.; Santos, E.S. Biomarkers, Prediction, and Prognosis in Non-Small Cell Lung Cancer: A Platform for Personalized Treatment. Clin. Lung Cancer, 2011, Nov; 12(6):360-8.
4. Passaro, A.; Cortesi, E.; de Marinis, F. Second-line treatment of non-smallcell lung cancer: chemotherapy or tyrosine kinase inhibitors? Expert Rev. Anticancer Ther., 2011, 11(10):1587-97.
5. Monica, V.; Scagliotti, G.; Ceppi, P.; Righi, L.; Cambieri, A.; Lo Iacono, M.; Saviozzi, S.; Volante, M.; Novello, S.; Papotti, M. Differential thymidylate synthase expression in different variants of large cell carcinoma of the lung. Clin. Cancer Res., 2009, 15:7547-7552.
6. Brugger, W.; Triller, N.; Blasinska-Morawiec, M.; Curescu, S.; Sakalauskas, R.; Manikhas, G.M.; Mazieres, J.; Whittom, R.; Ward, C.; Mayne, K.; Trunzer, K.; Cappuzzo, F. Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2011, 1; 29(31):4113-2
7. Linardou, H.; Dahabreh, I.J.; Bafaloukous, D.; Kosmidis, P.; Murray, S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell-lung-cancer. Lancet Oncol., 2008, 9:962-972
8. Janne, P.A.; Engelman, J.S.; Jhonson, B.E. Epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin. Cancer Res., 2006, 12:3652-3656
9. Sasaki, T.; Rodig, S.J.; Chirieac, L.R.; Jänne, P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer, 2010, 46(10):1773-80.
10. Gazdar, A.F. DNA repair and survival in lung cancer, the two faces of janus. N. Engl. J. Med., 2007, 356: 800-808
11. Fujii, T.; Toyooka, S.; Ichimura, K.; Fujiwara, Y.; Hotta, K.; Soh, J.; Suehisa, H.; Kobayashi, N.; Aoe, M.; Yoshino, T.; Kiura, K.; Date, H. ERCC1 predicts the response of cisplatin-based neoadjuvant chemotherapy in non small cell lung cancer. Lung Cancer, 2007, 59; 377-384.
12. Rosell, R.; Skrzypski, M.; Jassem, E.; Taron, M.; Bartolucci, R.; Sanchez, J.J.; Mendez, P.; Chaib, I.; Perez-Roca, L.; Szymanowska, A.; Rzyman, W.; Puma, F.; Kobierska-Gulida, G.; Farabi, R.; Jassem, J. BRCA1: a novel prognostic factor in resected NSCLC. PloS ONE, 2007, 2: 1129.
13. Chen, C.Y.; Chang, Y.L.; Shih, J.Y.; Lin, J.W.; Chen, K.Y.; Yang, C.H.; Yu, C.J.; Yang, P.C. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer, 2011, 74(1):132-8.
14. Mandrekar, S.J.; Sargent, D.J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol., 2009, 20; 27(24):4027-34.
15. Rosell, R.; Mendez, P.; Isla, D.; Taron, M. Platinum resistance related to a functional NER pathway. J. Thorac. Oncol., 2007, 2(12): 1063-6. (Pubitemid 350307897)
16. Rajewsky, M.; Muller, R. DNA repair and the cell cycle as targets in cancer therapy. The Cancer Handbook. Nature Publishing Group, London, pp. 1507-19, 2002.
17. Trispsianes, K.; Folkers, G.; Ab, E.; Dus, D.; Odijk, H.; Jasper, N.G. et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure, 2005, 13: 1849-58. (Pubitemid 41772953)
18. Britten, A.; Liu, D.; Tessier, A.; Hutchison, Murray. D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer, 2000, 89:453-7.
19. Youn, CK.; Kim, M.H.; Cho, H.J.; Kim, H.B.; Chang, I.Y.; Chung, M.H. et al. Oncogenic HRas up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res, 2004, 64:4849-57.
20. Metzger, R.; Leichman, C. G.; Danenberg, K. D.; Danenberg, P. V.; Lenz, H. J.; Hayashi, K.; et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol., 1998, 16(1), 309-316. (Pubitemid 28041614)
21. Dabholkar, M.; Bostick-Bruton, F.; Weber, C.; Bohr, V. A.; Egwuagu, C.; Reed, E. ERCC1andERCC2expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst., 1992, 84(19), 1512-1517.
22. Warnecke-Eberz, U.; Metzger, R.; Miyazono, F.; Baldus, S.E.; Neiss, S.; Brabender, J. et al. High specificity of quantitative excision repair crosscomplementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res., 2004, 10(11), 3794-3799. (Pubitemid 38697614)
23. Shirota, Y.; Stoehlmacher, J.; Brabender, J.; Xiong, Y. P.; Uetake, H.; Danenberg, K. D.; et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol., 2001, 19(23), 4298-4304. (Pubitemid 33096777)
24. Bewick, M. A.; Conlon, M. S.; Lafrenie, R. M. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J. Clin. Oncol, 2006, 24(36), 5645-5651. (Pubitemid 46631304)
25. Lord, R.V.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sánchez, J.M.; Gumerlock, P.H.; Tarón, M.; Sánchez, J.J.; Danenberg, K.D.; Danenberg, P.V.; Rosell, R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res., 2002, 8(7): 2286-91. (Pubitemid 34753602)
26. Olaussen, K.; Dunant, A.; Fouret, P.; Brambilla, E.; André, F.; Haddad, V.; et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N. Engl. J. Med., 2006, 335:983-91. (Pubitemid 44343542)
27. Cobo, M.; Isla, D.; Massuti, B.; Montes, A.; Sanchez, J.M.; Provencio, M.; Viñolas, N.; Paz-Ares, L.; Lopez-Vivanco, G.; Muñoz, M.A.; Felip, E.; Alberola, V.; Camps, C.; Domine, M.; Sanchez, J.J.; Sanchez-Ronco, M.; Danenberg, K.; Taron, M.; Gandara, D.; Rosell, R. Customizing cisplatin based on quantitative excision repair crosscomplementing mRNA ex.pression: a Phase III trial in non-small-cell lung cancer. J. Clin. Oncol., 2007, 25(19): 2747-54. (Pubitemid 47123183)
28. Simon, G. R.; Sharma, S.; Cantor, A.; Smith, P.; Bepler, G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 2005, 127(3), 978-983. (Pubitemid 40775532)
29. Bennett, E.J.; Harper, J.W. DNA damage: ubiquitin marks the spot. Nat. Struct. Mol. Biol., 2008, Jan; 15(1):20-2.
30. Lafarge, S.; Sylvain, V.; Ferrara, M.; Bignon, Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene, 2001, 20: 6597-6606. (Pubitemid 32980286)
31. Quinn, J.E.; Kennedy, R.D.; Mullan, P.B.; Gilmore, P.M.; Carty, M.; et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res., 2003, 63: 6221-6228. (Pubitemid 37255167)
32. Quinn, J.E.; James, C.R.; Stewart, G.E.; Mulligan, J.M.; White, P.; Chang, G.K.; Mullan, P.B.; Johnston, P.G.; Wilson, R.H.; Harkin, D.P. BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin. Cancer Res., 2007, 13: 7413-7420.
33. Wang, L.; Wei, J.; Qian, X.; Yin, H.; Zhao, Y.; Yu, L.; Wang, T.; Liu, B. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer. 2008; 8: 97.
34. Taron, M.; Rosell, R.; Felip, E.; Mendez, P.; Souglakos, J.; Ronco, M.S.; Queralt, C.; Majo, J.; Sanchez, J.M.; Sanchez, J.J.; Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet., 2004, 13(20): 2443-9. (Pubitemid 39377848)
35. Rosell, R.; Perez-Roca, L.; Sanchez, J.J.; Cobo, M.; Moran, T.; Chaib, I.; Provencio, M.; Domine, M.; Sala, M.A.; Jimenez, U.; Diz, P.; Barneto, I.; Macias, J.A.; De Las Peñas, R.; Catot, S.; Isla, D.; Sanchez, J.M.; Ibeas, R.; Lopez-Vivanco, G.; Oramas, J.; Mendez, P.; Reguart, N.; Blanco, R.; Taron, M. Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression, PLoS ONE, 2009, 4(5):e5133.
36. ClinicalTrial.gov. Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma (BREC). http://clinicaltrials.gov/ct2/show/NCT00617656 (Accessed Dec 20, 2011).
37. ClinicalTrial.gov. Randomized Customized Adjuvant Chemotherapy (GECPSCAT). http://clinicaltrials.gov/ct2/show/NCT00478699 (Accessed Nov 22, 2011).
38. Costi, M.P.; Ferrari, S.; Venturelli, A.; Calò, S.; Tondi, D.; Barlocco, D. Thymidylate synthase structure, function and implication in drug discovery. Curr. Med. Chem., 2005, 12:2241-2258. (Pubitemid 41179710)
39. Shirota, Y.; Stoehlmacher, J.; Brabender, J.; Xiong, Y.P.; Uetake, H.; Danenberg, K.D.; Groshen, S.; Tsao-Wei, D.D.; Danenberg, P.V.; Lenz, H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol., 2001, 19:4298-4304. (Pubitemid 33096777)
40. Shiga, H.; Heath, E.I.; Rasmussen, A.A.; Trock, B.; Johnston, P.G.; Forastiere, A.A.; Langmacher, M.; Baylor, A.; Lee, M.; Cullen, K.J. Prognostic value of p53, glutathione S-transferase pi, and hymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin. Cancer Res., 1999, 5:4097-4104. (Pubitemid 30013791)
41. Takamura, M.; Nio, Y.; Yamasawa, K.; Dong, M.; Yamaguchi, K.; Itakura, M. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs. 2002, 13:75-85. (Pubitemid 34169530)
42. Shintani, Y.; Ohta, M.; Hirabayashi, H.; Tanaka, H.; Iuchi, K.; Nakagawa, K.; Maeda, H.; Kido, T.; Miyoshi, S.; Matsuda, H. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer, 2004, 45:189-196. (Pubitemid 38891481)
43. Shih, C.; Chen, V.J.; Gossett, L.S.; Gates, S.B.; MacKellar, W.C.; Habeck, L.L.; Shackelford, K.A.; Mendelsohn, L.G.; Soose, D.J.; Patel, V.F.; Andis, S.L.; Bewley, J.R.; Rayl, E.A.; Moroson, B.A.; Beardsley, G.P.; Kohler, W.; Ratnam, M.; Schultz, R.M. LY231514, a pyrrolo 2, 3-d pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res., 1997, 57: 1116-1123. (Pubitemid 27138611)
44. Scagliotti, G.V.; Parikh, P.; von Pawel, J.; Biesma, B.; Vansteenkiste, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.; Digumarti, R.; Zukin, M.; Lee, J.S.; Mellemgaard, A.; Park, K.; Patil, S.; Rolski, J.; Goksel, T.; de Marinis, F.; Simms, L.; Sugarman, K.P.; Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol., 2008, 26: 3543-3551.
45. Ceppi, P.; Volante, M.; Saviozzi, S.; Rapa, I., Novello, S.; Cambieri, A.; Lo Iacono, M.; Cappia, S.; Papotti, M.; Scagliotti, G.V. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer, 2006, 107: 1589-1596. (Pubitemid 44546920)
46. Ozasa, H.; Oguri, T.; Uemura, T.; Miyazaki, M.; Maeno, K.; Sato, S.; Ueda, R. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci., 2010, 101: 161-166
47. Takezawa, K.; Okamoto, I.; Tsukioka, S.; Uchida, J.; Kiniwa, M.; Fukuoka, M.; Nakagawa, K. Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br. J. Cancer., 2010, 103: 354-361
48. Giaccone, G.; Herbst, R.S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R.B.; Schiller. J.H.; Von Pawel, J.; Pluzanska. A.; Gatzemeier, U.; Grous, J.; Ochs, J.S.; Averbuch, S.D.; Wolf, M.K.; Rennie, P.; Fandi, A.; Johnson, D.H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol., 2004, 22(5):777-84. (Pubitemid 41103588)
49. Herbst, R.S.; Giaccone, G.; Schiller, J.H.; Natale, R.B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J.A.; Wolf, M.K.; Krebs, A.D.; Averbuch, S.D.; Ochs, J.S.; Grous, J.; Fandi, A.; Johnson, D.H. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol., 2004, 22(5):785-94. (Pubitemid 41103589)
50. Keedy, V.L.; Temin, S.; Somerfield, M.R.; Beasley, M.B.; Johnson, D.H.; McShane, L.M.; Milton, D.T.; Strawn, J.R.; Wakelee, H.A.; Giaccone, G. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol., 2011, 29(15):2121-7.
51. Ettinger, D.S. Clinical implication of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 2006, 11 (4): 358-73.
52. Palazzo, A.; Iacovelli, R.; Cortesi, E. Past, present and future of targeted therapy in solid tumors. Curr. Cancer Drug Targets, 2010, 10 (5): 433-61.
53. Cohen, S.; Carpenter, G. Human epidermal growth factor: isolation and chemical and biological properties. Proc. Natl. Acad. Sci. USA, 1975, 72: 1317-1321.
54. Sporn, M.B.; Todaro, G.J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med., 1980, 303: 878-880.
55. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5: 341-354. (Pubitemid 40637826)
56. Wieduwilt, M.J.; Moasser, M.M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol. Life Sci., 2008, 65:1566-1584.
57. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med., 2008, 358(11):1160-74.
58. Jorissen, R.N.; Walker, F.; Pouliot, N.; Garrett, T.P.; Ward, C.W.; Burgess, A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res., 2003, 284(1): 31 -53. (Pubitemid 36331965)
59. Cappuzzo, F.; Hirsch, F.R.; Rossi, E.; Bartolini, S.; Ceresoli, G.L.; Bemis, L.; Haney, J.; Witta, S.; Danenberg, K.; Domenichini, I.; Ludovini, V.; Magrini, E.; Gregorc, V.; Doglioni, C.; Sidoni, A.; Tonato, M.; Franklin, W.A.; Crino, L.; Bunn, P.A.Jr.; Varella-Garcia, M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst., 2005, 97:643-655. (Pubitemid 40812628)
60. Hirsch, F.R.; Varella-Garcia, M.; McCoy, J.; West, H.; Xavier, A.C.; Gumerlock, P.; Bunn, P.A.Jr.; Franklin, W.A.; Crowley, J.; Gandara, D.R.; Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study. J. Clin. Oncol., 2005, 23: 6838-6845.
61. Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A.Jr.; Di Maria, M.V.; Veve, R.; Bremmes, R.M.; Barón, A.E.; Zeng, C.; Franklin, W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003, 21: 3798-3807. (Pubitemid 46606235)
62. Riely, G.J.; Marks, J.; Pao, W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc., 2009, 6 (2):201-5.
63. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 2005, 353(2):123-32. (Pubitemid 41058344)
64. Tsao, M.S.; Sakurada, A.; Cutz, J.C.; Zhu, C.Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F.A. Erlotinib in lung cancer -molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353(2):133-44. (Pubitemid 41058345)
65. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366: 527-37.
66. Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A.Jr.; Franklin, W.A.; Dziadziuszko, R.; Thatcher, N.; Chang, A.; Parikh, P.; Pereira, J.R.; Ciuleanu, T.; von Pawel, J.; Watkins, C.; Flannery, A.; Ellison, G.; Donald, E.; Knight, L.; Parums, D.; Botwood, N.; Holloway, B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer. J. Clin. Oncol., 2006, 24:5034-5042. (Pubitemid 46631407)
67. Kim, E.S.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Wu, Y.L.; Li, L.Y.; Watkins, C.L.; Sellers, M.V.; Lowe, E.S.; Sun, Y.; Liao, M.L.; Osterlind, K.; Reck, M.; Armour, A.A.; Shepherd, F.A.; Lippman, S.M.; Douillard, J.Y. Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): A randomised phase III trial. Lancet, 2008, 372:1809-1818.
68. Douillard, J.Y.; Shepherd, F.A.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Liao, M.L.; Bischoff, H.; Reck, M.; Sellers, M.V.; Watkins, C.L.; Speake, G.; Armour, A.A.; Kim, E.S. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J. Clin. Oncol., 2010, Feb 10; 28(5):744-52.
69. Schneider, C.P.; Heigener, D.; Schott-von-Römer, K.; Gütz, S.; Laack, E.; Digel, W.; Guschall, W.R.; Franke, A.; Bodenstein, H.; Schmidtgen, C.; Reck, M. Epidermal growth factor receptor related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J. Thorac. Oncol., 2008, 3 (12):1446-53.
70. Rosell, R.; Monzo, M.; Molina, F.; Martinez, E.; Pifarre, A.; Moreno, I.; Mate, J.L.; de Anta, J.M.; Sanchez, M.; Font, A. K-ras genotypes and prognosis in non-small-cell lung cancer. Ann. Oncol., 1995, 6:S15-S20.
71. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J.J.; Chewaskulyong, B.; Jiang, H.; Duffield, E.L.; Watkins, C.L.; Armour, A.A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 3; 361(10):947-57
72. Fukuoka, M.; Wu, Y.L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.S.; Sriuranpong, V.; Chao, T.Y.; Nakagawa, K.; Chu, D.T.; Saijo, N.; Duffield, E.L.; Rukazenkov, Y.; Speake, G.; Jiang, H.; Armour, A.A.; To, K.F.; Yang, J.C.; Mok, T.S. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). J. Clin. Oncol., 2011, 29 (21): 2866-74.
73. Zhou, C.; Wu, Y.L.; Chen, G.; Feng, J.; Liu, X.Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; Lu, S.; Zhang, L.; Hu, C.; Hu, C.; Luo, Y.; Chen, L.; Ye, M.; Huang, J.; Zhi, X.; Zhang, Y.; Xiu, Q.; Ma, J.; Zhang, L.; You, C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol., 2011, 12(8):735-42.
74. Rosell, R.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Cardenal, F.; Garcia Gomez, R.; Pallares, C.; Sanchez, J.M.; Porta, R.; Cobo, M.; Di Seri, M.; Garrido Lopez, P.; Insa, A.; De Marinis, F.; Corre, R.; Carreras, M.; Carcereny, E., Taron, M.; Paz-Ares, L.G.; Spanish Lung Cancer Group. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J. Clin. Oncol., 2011, 29: (suppl; abstr 7503).
75. Morris, S.W.; Kirstein, M.N.; Valentine, M.B.; Dittmer, K.G.; Shapiro, D.N.; Saltman, D.L.; Look, A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 1994, 4, 263(5151):1281-4. (Pubitemid 24107549)
76. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature, 2007, 448(7153):561-6. (Pubitemid 47206930)
77. Takeuchi, K.; Choi, Y.L.; Togashi, Y.; Soda, M.; Hatano, S.; Inamura, K.; Takada, S.; Ueno, T.; Yamashita, Y.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y.; Mano, H. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res., 2009, May 1; 15(9):3143-9.
78. Rikova K.; Guo, A.; Zeng, Q.; Possemato, A.; Yu, J.; Haack, H.; Nardone, J.; Lee, K.; Reeves, C.; Li, Y.; Hu, Y.; Tan, Z.; Stokes, M.; Sullivan, L.; Mitchell, J.; Wetzel, R.; Macneill, J.; Ren, JM.; Yuan, J.; Bakalarski, C.E.; Villen, J.; Kornhauser, J.M.; Smith, B.; Li, D.; Zhou, X.; Gygi, S.P.; Gu, T.L.; Polakiewicz, R.D.; Rush, J.; Comb, M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131(6):1190-203. (Pubitemid 350235027)
79. Weinstein, I.B.; Joe, A. Oncogene addiction. Cancer Res., 2008, 68(9):3077-80.
80. Inamura K.; Takeuchi K.; Togashi, Y.; Hatano, S.; Ninomiya, H.; Motoi, N.; Mun, M.Y.; Sakao, Y.; Okumura, S.; Nakagawa, K.; Soda, M.; Choi, Y.L.; Mano, H.; Ishikawa, Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol., 2009, 22(4):508-15.
81. Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; Settleman, J.; Kobayashi, S.; Mark, E.J.; Rodig, S.J.; Chirieac, L.R.; Kwak, E.L.; Lynch, T.J.; Iafrate, A.J. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol., 2009, 27(26):4247-53.
82. Koivunen, J.P.; Mermel, C.; Zejnullahu, K.; Murphy, C.; Lifshits, E.; Holmes, A.J.; Choi, H.G.; Kim, J.; Chiang, D.; Thomas, R.; Lee, J.; Richards, W.G.; Sugarbaker, D.J.; Ducko, C.; Lindeman, N.; Marcoux, J.P.; Engelman, J.A.; Gray, N.S.; Lee, C.; Meyerson, M.; Jänne, P.A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res., 2008, 14(13):4275-83.
83. Solomon, B.; Varella-Garcia, M.; Camidge, D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol., 2009, (12):1450-4.
84. Crinò, L.; Kim, D.; Riely, G.J; Janne, P.A.; Blackhall, F.H.; Camidge, D.R; Hirsh, V.; Mok, T.; Solomon, B.J.; Park, K.; Gadgeel, S.M.; Martins, R.; Han, J.; De Pas, T.M.; Bottomley, A.; Polli, A.; Petersen, J.; Tassell, V.R.; Shaw, A.T. 2011 ASCO Annual Meeting. J. Clin. Oncol., 2011, 29 (suppl): abstr. 7514.
85. ClinicalTrial.gov. An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene. http://clinicaltrial.gov/ct2/show/NCT00932893 (Accessed Jan 4, 2012).
86. Pelicci, G.; Giordano, S.; Zhen, Z.; Salcini, A.E.; Lanfrancone, L.; Bardelli, A.; Panayotou, G.; Waterfield, M.D.; Ponzetto, C.; Pelicci, P.G. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene, 1995, 10 (8): 1631-8.
87. Weidner, K.M.; Di Cesare, S.; Sachs, M.; Brinkmann, V.; Behrens, J.; Birchmeier, W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature, 1996; 384(6605): 173-6. (Pubitemid 26386473)
88. Furge, K.A.; Zhang, Y.W.; Vande Woude, G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 2000, 19 (49): 5582-9.
89. Gual, P.; Giordano, S.; Anguissola, S.; Parker, P.J.; Comoglio, P.M. Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling. Oncogene, 2000, 20 (2): 156-66.
90. Bean, J.; Brennan, C.; Shih, J.Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.C.; Yu, C.J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, SF.; Yang, P.C.; Miller, V.; Ladanyi, M.; Yang, C.H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA, 2007, 104(52):20932-7.
91. Cappuzzo, F.; Jänne, P.A.; Skokan, M.; Finocchiaro, G.; Rossi, E.; Ligorio, C.; Zucali, P.A.; Terracciano, L.; Toschi, L.; Roncalli, M.; Destro, A.; Incarbone, M.; Alloisio, M.; Santoro, A.; Varella-Garcia, M. MET increased gene copy number and primary resistance to gefitinib therapy in non-smallcell lung cancer patients. Ann. Oncol., 2009, (2):298-304.
92. Chen, H.J.; Mok, T.S.; Chen, Z.H.; Guo, A.L.; Zhang, X.C.; Su, J.; Wu, Y.L. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitorresistant Chinese non-small cell lung cancer. Pathol. Oncol. Res., 2009, 15(4):651-8.
93. Kubo, T.; Yamamoto, H.; Lockwood, W.W.; Valencia, I.; Soh, J.; Peyton, M.; Jida, M.; Otani, H.; Fujii, T.; Ouchida, M.; Takigawa, N.; Kiura, K.; Shimizu, K.; Date, H.; Minna, J.D.; Varella-Garcia, M.; Lam, W.L.; Gazdar, A.F.; Toyooka, S. MET gene amplification or EGFR mutation activate MET in lung. cancers untreated with EGFR tyrosine kinase inhibitors. Int. J. Cancer, 2009, 124(8):1778-84.
94. Kong-Beltran, M.; Seshagiri, S.; Zha, J.; Zhu, W.; Bhawe, K.; Mendoza, N.; Holcomb, T.; Pujara, K.; Stinson, J.; Fu, L.; Severin, C.; Rangell, L.; Schwall, R.; Amler, L.; Wickramasinghe, D.; Yauch, R. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res., 2006, 66(1):283-9. (Pubitemid 43166034)
95. Ma, P.C.; Kijima, T.; Maulik, G.; Fox, E.A.; Sattler, M.; Griffin, J.D.; Johnson, B.E.; Salgia, R. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res., 2003, 63(19):6272-81. (Pubitemid 37255174)
96. Benedettini, E.; Sholl, L.M.; Peyton, M.; Reilly, J.; Ware, C.; Davis, L.; Vena, N.; Bailey, D.; Yeap, B.Y.; Fiorentino, M.; Ligon, A.H.; Pan, B.S.; Richon, V.; Minna, J.D.; Gazdar, A.F.; Draetta, G.; Bosari, S.; Chirieac, L.R.; Lutterbach, B.; Loda, M. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol., 2010, 177(1):415-23.
97. Nakamura Y.; Niki, T.; Goto, A.; Morikawa, T.; Miyazawa, K.; Nakajima, J.; Fukayama, M. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci., 2007, 98(7):1006-13. (Pubitemid 46865384)
98. Xu, L.; Nilsson, M.B.; Saintigny, P.; Cascone, T.; Herynk, M.H.; Du, Z.; Nikolinakos, P.G.; Yang, Y.; Prudkin, L.; Liu, D.; Lee, J.J.; Johnson, F.M.; Wong, K.K.; Girard, L.; Gazdar, A.F.; Minna, J.D.; Kurie, J.M.; Wistuba, I.I.; Heymach, J.V. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene, 2010, 6; 29(18):2616-27.
99. Spigel D.; Ervin, T.; Ramlau, R.; Daniel, D.; Goldschmidt, J.; Krzakowski, M.; Godbert, B.; Yu, W.; Patel, P.H.; Peterson, A. Randomised multicenter double-blind placebo-controlled Phase II study evaluating MetMAb, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Ann. Oncol., 2010, 21 (suppl 8): abstr. LBA15.
100. Sequist, L.V.; von Pawel, J.; Garmey, E.G.; Akerley, W.L.; Brugger, W.; Ferrari, D.; Chen, Y.; Costa, D.B.; Gerber, D.E.; Orlov, S.; Ramlau, R.; Arthur, S.; Gorbachevsky, I.; Schwartz, B.; Schiller, J.H. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol., 2011, 29(24):3307-15.